NOTA Labs
NOTA Labs is a University of Michigan spinout developing proprietary nitric oxide delivery systems (NOGEN electrochemical platform and LANOR UV-LED platform) plus a catheter lock solution for hospital, ambulatory, and home-care applications. Pre-commercial, investigational-use only.
- Company typePrivate
- Founded2014
- HeadquartersAnn Arbor, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NOTA Labs does
NOTA Laboratories (doing business as NOTA Labs) is a University of Michigan spinout founded in 2014 and headquartered in Ann Arbor, Michigan. The company is a development-stage medical device firm focused on proprietary nitric oxide (NO) delivery systems that leverage NO's antiviral, antimicrobial, anti-inflammatory, anti-thrombotic, and vasodilatory properties. Products are explicitly for investigational use only and not available for commercial sale, with no disclosed revenue to date.
The company's core technology rests on two patented platform systems. NOGEN is an electrochemical system that generates high-volume nitric oxide (up to 500 ppm) continuously for up to 6 months by reducing nitrite, regulated by varying current and voltage with multi-sensor in-line controls; it targets hospital use cases including persistent pulmonary hypertension in newborns (PPHN), open-heart surgery (thrombosis and SIRS prevention), lung transplantation, and ECMO. LANOR is a UV-LED photochemical system that converts a solid NO donor molecule via light energy using a proprietary film cassette, producing a compact, lightweight, battery-operated device intended for home and ambulatory use, particularly for COPD patients. A catheter lock solution rounds out the pipeline. Single-use disposable NO technologies have been separated into a spinout, NOxygen Therapeutics.
NOTA's anticipated business model is hardware sales of the NOGEN and LANOR systems plus recurring consumable revenue from chemical cartridges and film cassettes, though no pricing has been disclosed. GTM is multi-modal: enterprise field sales targeting hospital systems for NOGEN, sales-led development partnerships with medical device distributors (notably the NGK/CAIRE joint development agreement for bundled oxygen-concentrator-plus-NO distribution into the COPD market), and a future direct-to-consumer motion for LANOR in home care. Capital structure includes a $4.3 million NIH SBIR grant and a second venture round led by Pegasus Tech Ventures.
NOTA Labs firmographics
Firmographics- Name
- NOTA Labs
- Legal name
- NOTA Laboratories
- Website
- https://notalabs.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NOTA Labs is a University of Michigan spinout developing proprietary nitric oxide delivery systems (NOGEN electrochemical platform and LANOR UV-LED platform) plus a catheter lock solution for hospital, ambulatory, and home-care applications. Pre-commercial, investigational-use only.
- Ownership category
- akta.pro rank
NOTA Labs industry classification
Industry- Product category
- Nitric Oxide Delivery Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)
- akta.pro secondary industries
- Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Personal Protective Equipment (PPE) (Gloves, Masks/Respirators, Gowns, Face Shields) (HLAHANAF)
Keywords
Where NOTA Labs is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NOTA Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Hardware Sales: Pre-commercial development stage. Revenue anticipated from sale of NO generation systems (NOGEN and LANOR) along with associated disposable components (chemical cartridges, film cassettes). Products under development for FDA approval.
Go-to-market motion3 records
NOTA Labs product offering
Product offeringCore offering
NOTA Labs develops proprietary nitric oxide (NO) delivery platform technologies for therapeutic applications in respiratory, inflammatory, infectious, cardiovascular, and catheter-related conditions. The portfolio includes the NOGEN electrochemical system for high-volume hospital use, the LANOR UV-LED photochemical system for compact home/ambulatory use, and an NO-releasing intravascular catheter lock solution for infection and thrombosis prevention. All products are currently for investigational use only and not commercially available.
Product overview
NOTA Labs offers a portfolio of nitric oxide (NO) delivery systems comprising two platform technologies: the NOGEN System (electrochemical NO generation for hospital/high-volume applications) and the LANOR System (UV-LED photochemical NO generation for home/ambulatory use), along with a catheter lock solution for preventing catheter-related infections. All products leverage NO's antiviral, antimicrobial, anti-thrombotic, anti-inflammatory, and vasodilatory properties.
Differentiator
Problem solved
Functional benefit
Products and services
- NOGEN System Electrochemical nitric oxide generation system that produces up to 500 ppm NO continuously for up to 6 months using inexpensive chemical cartridges; designed for hospital use in PPHN, open heart surgery (prevention of thrombosis and SIRS), lung transplantation, and ECMO/extracorporeal circulation applications. Products are for investigational use only and not commercially available.
- LANOR System UV-LED based photochemical nitric oxide generation system that converts a solid NO donor molecule from a film cassette using light energy; compact, lightweight, and battery-operated, enabling home/ambulatory use for COPD, chronic respiratory infections, and emergency applications. Products are for investigational use only and not commercially available.
- Catheter Lock Solution Novel nitric oxide-releasing intravascular (IV) catheter lock solution that delivers NO inside catheter walls to prevent microbial growth and clotting, reducing risk of catheter-related bloodstream infection (CRBSI) and catheter thrombosis for healthcare facilities.
Quantifiable outcome
- NOGEN generates up to 500 ppm NO, compared to traditional tank-based systems costing $100/hour
- +1 more outcomes
Companies that use NOTA Labs
Customer profileSegments3 records
Ideal customer profiles3 records
NOTA Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
NOTA Labs partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- NGK Spark Plugs (Nagoya, Japan)coreNOTA signed a Joint Development Agreement with NGK Spark Plugs for development and manufacturing collaboration. NGK owns CAIRE Inc., a major supplier of oxygen concentrators for home, clinic, and hospital use. The collaboration aims to integrate NOTA's NO systems with CAIRE oxygen concentrators to provide broader solutions for COPD patients, potentially reducing exacerbations and improving quality of life. NGK brings expertise in design, engineering, and manufacturing to accelerate products to market.
- University of MichigancoreNOTA is a University of Michigan spinout company founded in 2014. The LANOR system was developed in collaboration with the University of Michigan. Dr. Mark Meyerhoff, the company's founder and chairman, leads research at the University's Department of Chemistry. Multiple advisory board members are University of Michigan faculty, and the company collaborates with Dr. Robert Bartlett's lab for ECMO and cardiac surgery applications.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
NOTA Labs competitors and assessment
Company assessmentDirect peers
- Beyond Air: Commercial-stage developer of nitric oxide delivery systems (LungFit) targeting respiratory infections and COPD. Directly comparable as a NO-generation platform company with hospital and home-use ambitions overlapping NOTA's NOGEN and LANOR systems.
- Vero Biotech: Developer of GENOSYL, an FDA-approved tankless inhaled nitric oxide delivery system. Direct competitor in on-demand NO generation for hospital iNO therapy, targeting the same neonatal/PPHN and cardiac surgery markets as NOGEN.
- Mallinckrodt Pharmaceuticals: Markets INOMAX, the FDA-approved standard-of-care inhaled nitric oxide therapy for neonatal PPHN and related indications. The entrenched incumbent in the iNO market that NOTA's cost-advantaged electrochemical system must displace.
- Third Pole Therapeutics: Emerging developer of portable, on-demand nitric oxide generation technology for hospital and potentially home use. Directly comparable technology approach to NOTA's NOGEN and LANOR electrochemical/photochemical platforms.
Emerging players
- Bellerophon Therapeutics: Developed INOpulse, a pulsed inhaled nitric oxide delivery system for pulmonary hypertension and cardiopulmonary conditions. Comparable as a NO-delivery therapeutic developer, though its commercial trajectory has been constrained.
Broad incumbents
- Medtronic: Global medtech leader whose heart-lung machines and ECMO systems are the platforms into which NOTA's NOGEN system would integrate during open heart surgery. Comparable as the dominant incumbent in the cardiac surgery device ecosystem NOTA targets.
- Terumo: Manufacturer of heart-lung machines, oxygenators, and ECMO systems used in cardiac surgery — the same procedural setting where NOGEN is positioned to deliver NO as a sweep gas. Broad incumbent in the cardiopulmonary bypass workflow.
- Becton, Dickinson and Company (BD): Major manufacturer of intravascular catheters and catheter maintenance solutions, overlapping with NOTA's catheter lock solution for preventing CRBSI and thrombosis. Large incumbent with established hospital catheter relationships.
- ICU Medical: Manufacturer of IV catheters, catheter connectors, and needlefree connectors used in hospital infusion therapy. Comparable as an established player in the catheter care space where NOTA's NO-releasing lock solution competes.
Others
- Air Liquide Healthcare: Global medical gases supplier that, alongside Linde/Praxair, supplies tank-based nitric oxide to hospitals. Indirect competitor and potential partner as the industry transitions from tank-based delivery to on-demand generation systems like NOTA's.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NOTA Labs social profiles
Digital presenceNOTA Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
NOTA Labs leadership team
Management profileNumber of profiles
Profiles8 records
NOTA Labs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NOTA Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NOTA Labs
What does NOTA Labs do?
NOTA Labs develops proprietary nitric oxide (NO) delivery platform technologies for therapeutic applications in respiratory, inflammatory, infectious, cardiovascular, and catheter-related conditions. The portfolio includes the NOGEN electrochemical system for high-volume hospital use, the LANOR UV-LED photochemical system for compact home/ambulatory use, and an NO-releasing intravascular catheter lock solution for infection and thrombosis prevention. All products are currently for investigational use only and not commercially available.
Is NOTA Labs a public or private company?
NOTA Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was NOTA Labs founded?
NOTA Labs was founded in 2014. It employs 11 to 50 people.
Where is NOTA Labs based?
NOTA Labs is headquartered in Ann Arbor, United States, in the North America region.
How does NOTA Labs make money?
One revenue line is on record: medical Device Hardware Sales.
Who are NOTA Labs's main competitors?
Direct peers on record are Beyond Air, Vero Biotech, Mallinckrodt Pharmaceuticals and Third Pole Therapeutics. Bellerophon Therapeutics is listed as an emerging player. Broad incumbents are Medtronic, Terumo, Becton, Dickinson and Company (BD) and ICU Medical. Air Liquide Healthcare is listed as an others.
Does NOTA Labs have an API?
No public API is recorded for NOTA Labs.
What industry is NOTA Labs in?
NOTA Labs's product category is Nitric Oxide Delivery Medical Devices. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC), with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 334510 and its SIC code is 3845.